Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| LifeMD, Inc.CVLB · Entity 6521 | Chief Financial Officer | March 01, 2019 | March 04, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
LifeMD, Inc.
Report date March 01, 2019 · Filed March 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Options to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.28 · Expires 2027-09-30 | Direct | 150,000 |
Reported balance
After 2017-10-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-10-01 · Other · Acquired 150,000 · Balance 150,000 F1: These options were previously reported by Mr. Kalkstein on his Form 3 filed with the Commission on November 13, 2017. Pursuant to an amendment to his consulting agreement with Conversion Labs, Inc., the exercise price of these options were reduced from $0.40 to $0.28. |
| Options to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $0.28 · Expires 2027-09-30 | Direct | 150,000 |
Reported balance
After 2019-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-03-01 · Other · Acquired 150,000 · Balance 150,000 F2: Pursuant to an amendment to his consulting agreement with Conversion Labs, Inc., the exercise price of these options were reduced from $0.40 to $0.28 and now vest on March 31, 2019. Additionally, the 200,000 to be issued to Mr. Kalkstein pursuant to his consulting agreement were cancelled and Mr. Kalkstein also has forgone $32,500 owed to him by Conversion Labs, Inc. |
Filing footnotes · ownership attribution and instrument terms
F1: These options were previously reported by Mr. Kalkstein on his Form 3 filed with the Commission on November 13, 2017. Pursuant to an amendment to his consulting agreement with Conversion Labs, Inc., the exercise price of these options were reduced from $0.40 to $0.28.
F2: Pursuant to an amendment to his consulting agreement with Conversion Labs, Inc., the exercise price of these options were reduced from $0.40 to $0.28 and now vest on March 31, 2019. Additionally, the 200,000 to be issued to Mr. Kalkstein pursuant to his consulting agreement were cancelled and Mr. Kalkstein also has forgone $32,500 owed to him by Conversion Labs, Inc.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2019 Filed Mar 4, 2019 11:03 UTC | LifeMD, Inc. CVLB · Entity 6521 | OtherOptions to purchase Common Stock · Derivative | 150,000 | $0.28 Strike: $0.28 | $42,000.00 |
DisclosureSEC source: 0001213900-19-003447 · ownership.xml · derivative · entry 2 Kalkstein Robert L · CIK 0001526136 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-09-30 F2 · kind: Pursuant to an amendment to his consulting agreement with Conversion Labs, Inc., the exercise price of these options were reduced from $0.40 to $0.28 and now vest on March 31, 2019. Additionally, the 200,000 to be issued to Mr. Kalkstein pursuant to his consulting agreement were cancelled and Mr. Kalkstein also has forgone $32,500 owed to him by Conversion Labs, Inc. Read SEC document |
| October 01, 2017 Filed Mar 4, 2019 11:03 UTC | LifeMD, Inc. CVLB · Entity 6521 | OtherOptions to purchase Common Stock · Derivative | 150,000 | $0.28 Strike: $0.28 | $42,000.00 |
DisclosureSEC source: 0001213900-19-003447 · ownership.xml · derivative · entry 1 Kalkstein Robert L · CIK 0001526136 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2027-09-30 F1 · kind: These options were previously reported by Mr. Kalkstein on his Form 3 filed with the Commission on November 13, 2017. Pursuant to an amendment to his consulting agreement with Conversion Labs, Inc., the exercise price of these options were reduced from $0.40 to $0.28. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.